scholarly journals Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics

Vaccine ◽  
2019 ◽  
Vol 37 (50) ◽  
pp. 7394-7395 ◽  
Author(s):  
Johan Vekemans ◽  
Vasee Moorthy ◽  
Brigitta Giersing ◽  
Martin Friede ◽  
Joachim Hombach ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Research And Development ◽  
World Health Organization ◽  
Virus Vaccine ◽  
World Health ◽  
Vaccine Research ◽  
Product Characteristics ◽  
Syncytial Virus ◽  
Health Organization ◽  
Respiratory Syncytial Virus Vaccine

scholarly journals The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics

2019 ◽  
Vol 69 (5) ◽  
pp. 877-883 ◽  
Author(s):  
Johan Vekemans ◽  
Fernando Gouvea-Reis ◽  
Jerome H Kim ◽  
Jean-Louis Excler ◽  
Pierre R Smeesters ◽  
...  
Keyword(s):  
Research And Development ◽  
World Health Organization ◽  
Vaccine Efficacy ◽  
Group A Streptococcus ◽  
World Health ◽  
Product Characteristics ◽  
Technology Roadmap ◽  
Development Technology ◽  
Group A ◽  
Health Organization

Abstract Group A Streptococcus (GAS) infections result in a considerable underappreciated burden of acute and chronic disease globally. A 2018 World Health Assembly resolution calls for better control and prevention. Providing guidance on global health research needs is an important World Health Organization (WHO) activity, influencing prioritization of investments. Here, the role, status, and directions in GAS vaccines research are discussed. WHO preferred product characteristics and a research and development technology roadmap, briefly presented, offer an actionable framework for vaccine development to regulatory and policy decision making, availability, and use. GAS vaccines should be considered for global prevention of the range of clinical manifestations and associated antibiotic use. Impediments related to antigen diversity, safety concerns, and the difficulty to establish vaccine efficacy against rheumatic heart disease are discussed. Demonstration of vaccine efficacy against pharyngitis and skin infections constitutes a key near-term strategic goal. Investments and collaborative partnerships to diversify and advance vaccine candidates are needed.

Chitosan alters inactivated respiratory syncytial virus vaccine elicited immune responses without affecting lung histopathology in mice

Vaccine ◽  
2019 ◽  
Vol 37 (30) ◽  
pp. 4031-4039 ◽  
Author(s):  
Abenaya Muralidharan ◽  
Marsha S. Russell ◽  
Louise Larocque ◽  
Caroline Gravel ◽  
Simon Sauvé ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Immune Responses ◽  
Virus Vaccine ◽  
Lung Histopathology ◽  
Syncytial Virus ◽  
Respiratory Syncytial Virus Vaccine

scholarly journals Meeting report: Initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017

Vaccine ◽  
2019 ◽  
Vol 37 (50) ◽  
pp. 7408-7418 ◽  
Author(s):  
Sami L. Gottlieb ◽  
Birgitte K. Giersing ◽  
Julian Hickling ◽  
Rebecca Jones ◽  
Carolyn Deal ◽  
...  
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
World Health Organization ◽  
World Health ◽  
Meeting Report ◽  
Product Characteristics ◽  
Health Organization ◽  
Simplex Virus

scholarly journals Progress toward a Respiratory Syncytial Virus Vaccine

2016 ◽  
Vol 23 (3) ◽  
pp. 186-188 ◽  
Author(s):  
Kathleen M. Neuzil
Keyword(s):  
Viral Load ◽  
Respiratory Syncytial Virus ◽  
Virus Vaccine ◽  
Effective Vaccine ◽  
Vaccine Candidates ◽  
Target Populations ◽  
Link Type ◽  
History Of ◽  
Syncytial Virus ◽  
Respiratory Syncytial Virus Vaccine

ABSTRACTIn accompanying papers (P. L. Acosta, M. T. Caballero, and F. P. Polack, Clin Vaccine Immunol 23:189–195, 2016,http://dx.doi.org/10.1128/CVI.00609-15; M. Vissers, I. M. L. Ahout, M. I. de Jonge, and G. Ferwerda, Clin Vaccine Immunol 23:243–245, 2016,http://dx.doi.org/10.1128/CVI.00590-15) in this issue ofClinical and Vaccine Immunology, the history of and immune mechanisms underlying vaccine-enhanced respiratory syncytial virus (RSV) disease and of investigations of mucosal antibodies and their association with viral load in RSV-infected children, respectively, are described. This commentary discusses RSV vaccine candidates, target populations, and the challenges associated with achieving a safe and effective vaccine.

Sign in / Sign up

Export Citation Format

Share Document